Biomarkers of inflammation in CAA, BICAA
Research type
Research Study
Full title
Biomarkers of inflammation to understand brain haemorrhage in cerebral amyloid angiopathy.
IRAS ID
342116
Contact name
David Werring
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2024/07/278, Data Protection Office
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Cerebral amyloid angiopathy (CAA) is a very common age-related condition, due to the deposition of peptide (amyloid-beta) in the walls of small arterioles of the brain.
CAA is an important cause of stroke and cognitive impairment (including dementia).
The most serious consequence of CAA is due to brain haemorrhage, the most severe kind of stroke, with a one-month risk of death of around 40%.Although CAA is extremely common in the general older population (around 23% in a recent studies), only a minority of those affected develop intracranial haemorrhages.
The underlying mechanisms remain uncertain, but it clear that the deposition of amyloid alone is not sufficient to cause haemorrhage.
A better understanding of why it occurs is vital to prevent disability from recurrent brain haemorrhage.
We recently found preliminary evidence of blood vessel inflammation in people with CAA and would like to see if this could explain why brain haemorrhages occur and ultimately help us to develop new preventive treatments.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
25/LO/0275
Date of REC Opinion
21 May 2025
REC opinion
Further Information Favourable Opinion